•   One recent RCT (NCT02465580) showed that low-dose IL-2 treatment in active SLE patients did not meet its primaryendpoint of SRI-4 at 12 weeks but achieved higher complete remission rates than placebo in patients with LN and waswell tolerated. Here, IL2 is linked to systemic lupus erythematosus.